<DOC>
	<DOCNO>NCT02572609</DOCNO>
	<brief_summary>evaluate bioavailability ambroxol hydrochloride soft pastille ( test formulation ) , manufacture Bolder Arzneimittel GmbH &amp; Co. KG Boehringer Ingelheim compare ambroxol hydrochloride syrup ( Mucosolvan® adult syrup ) , manufacture Boehringer Ingelheim Brasil Química e Farmacêutica Ltda .</brief_summary>
	<brief_title>Relative Bioavailability Study Between Two Formulations Containing Ambroxol Hydrochloride</brief_title>
	<detailed_description />
	<mesh_term>Ambroxol</mesh_term>
	<criteria>Inclusion criterion : The volunteer 18 50 year old , man woman pregnant and/or breastfeeding regime , undertakes use effective birth control method throughout study period . Body mass index high equal 18.5 low equal 29.9 kg/m2 . The volunteer good health status clinically significant disease , discretion physician Medical History , measurements Blood Pressure , Pulse Temperature , Physical Examination , Electrocardiogram complementary Laboratory Tests . Volunteer able understand nature objective study , include risk adverse effect , intention cooperate investigator act accordance requirement entire trial , confirm signing Informed Consent Form . Exclusion criterion : Volunteer know hypersensitivity study drug chemically related compound ; excipients describe adult syrup and/or soft pastille , example , sorbitol ( fructose ) . History presence gastrointestinal liver disease , condition interferes absorption , distribution , excretion metabolism drug . Use maintenance therapy drug , except contraceptive . Diseases health problem History liver , renal , pulmonary , gastrointestinal , neurological , hematological , psychiatric , cardiac allergic disease cause require pharmacological treatment consider clinically relevant investigator ; Electrocardiographic finding recommend , discretion investigator participation study . Additional laboratory test result normal value accord standard Potocol , unless consider clinically significant investigator . Tabagism . Daily intake 5 cup coffee tea . History alcohol drug abuse . Use regular medication within 2 week prior initiation study , use medication one week start study . Hospitalization reason 8 week start first treatment period study . Treatment within 3 month prior study treatment initiation drug know welldefined toxic potential large organ . Participation pharmacokinetic study 300 mL blood take ingested study drug within six month precede treatment start study . Donation loss 450 mL blood within three month precede study donate 1500 mL within 12 month prior study treatment initiation . PreConfinement Examination Results Positive result urine βHCG test carry female volunteer . Other condition Any condition prevents participation study judge investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>